PRECISE-AD Study:Trying a new treatment for Early Alzheimer's disease
The PRECISE-AD study is a phase 1 clinical trial, sponsored by ProMis Neurosciences, for people with mild cognitive impairment (MCI) to mild dementia due to Alzheimer's disease. It tests a new antibody treatment (PMN310), given by IV, that is designed to help slow down the disease. PMN310 is investigational and not yet approved by the FDA.
Study highlights
Key information about the PRECISE-AD study
- Age 50 and older
- Early Alzheimer's Disease
- Study partner (friend or family) available
- Infusion
- Study zone: Southern California
Study goal and design
Advancing precision medicine in early Alzheimer's disease
The PRECISE-AD study is testing a new IV treatment called PMN310 in people with early Alzheimer's. It looks at whether the drug is safe, well-tolerated, how it works in the body, and whether it might help slow the disease by targeting amyloid-beta.
Study-related care and support
Comprehensive medical oversight and biomarker analysis
While contributing to research, participants receive:
- The possibility to receive PMN310 investigational study medication
- Advanced biomarker testing and brain imaging
- Regular cognitive assessments and memory evaluations
- Study visits with qualified medical professionals
All medical and travel costs related to the study are covered.
Volunteer journey
A structured research experience
Express your interest
Answer a questionnaire to check preliminary criteria.
Meet the study team
Complete a detailed brain and memory evaluation.
Begin treatment (or placebo)
Receive PMN310 or placebo by IV infusion once every 4 weeks, for a total of 12 infusions over 1 year.
Continue the study
Be monitored during follow-up visits, and get health check-ups to observe any changes in cognition.
Ready to get involved?Join the PRECISE-AD study.
Contribute to progress, support research, help others, and care for your health.